Cellular Intelligence firma un acuerdo con Novo Nordisk para avanzar en la terapia celular contra el Parkinson
'Este programa de terapia celular para el Parkinson es verdaderamente innovador y ejemplifica la poderosa convergencia de un emocionante descubrimiento académico con la calidad inquebrantable de un líder farmacéutico global.'
Valoración
A small Israeli biotech has secured a partnership with one of the world's largest drugmakers, signaling growing confidence in cell-based approaches to Parkinson's disease. The deal validates the scientific platform and provides financial runway for early-stage trials. The key question is whether this therapy can overcome the manufacturing and delivery hurdles that have stalled similar programs.